Severity Reduced With Mpox Reinfection, Postvaccination Infection
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 11, 2023 -- The clinical features and outcomes of mpox reinfection and infection postvaccination are less clinically severe than initial infection, according to a global case series published online Sept. 4 in The Lancet Infectious Diseases.
Aniruddha Hazra, M.D., from the University of Chicago Medicine, and colleagues describe the epidemiological and clinical characteristics of mpox in individuals with past infection or vaccination in a global case series. Data were provided from international collaborators from nine countries on individuals with polymerase chain reaction-confirmed mpox after documented previous infection or vaccination between May 11, 2022, and June 30, 2023.
Mpox infections were reported in 37 gay and bisexual men who have sex with men: seven had mpox reinfections, 29 had infections that occurred after two vaccine courses, and one had an infection that met the criteria for both reinfection and infection after vaccination. The researchers found that compared with the initial infection, those with natural immunity after initial infection had a shorter disease course with less mucosal disease upon reinfection. Few lesions, little mucosal disease, and minimal analgesia requirements characterized infections postvaccination. Oral tecovirimat was received by two people. No deaths and no bacterial superinfections occurred, and all individuals were managed in the ambulatory clinic; one patient was admitted to the hospital for a necrotizing neck lesion.
"These findings support the literature, signaling that vaccinations might reduce duration and severity," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
COVID-19 Vaccination Not Tied to Adverse Pregnancy Outcomes
TUESDAY, June 25, 2024 -- mRNA COVID-19 vaccination during pregnancy is not associated with an increased risk of adverse pregnancy outcomes, according to a study published in the...
FDA Approves Capvaxive Pneumococcal 21-Valent Conjugate Vaccine
FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved the Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal...
No Evidence That Live Vaccines Are Unsafe for Patients on Dupilumab
FRIDAY, June 14, 2024 -- There is no evidence to suggest that administration of live vaccines to patients receiving dupilumab is unsafe, and vaccine efficacy is not affected by...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.